Arachidonic acid is an omega-6 fatty acid that is present in the phospholipids (especially phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositides) of membranes of the body's cells, and is abundant in the brain. It is the counterpart to the saturated arachidic acid found in peanut oil.
Patients with schizophrenia exhibit reduced red blood cell levels of certain polyunsaturated fatty acids , results from a systematic review and meta-analysis show.
Patients with schizophrenia exhibit reduced red blood cell levels of certain polyunsaturated fatty acids, results from a systematic review and meta-analysis show.
Results from a systematic review and meta-analysis show that erythrocyte membrane concentrations of certain polyunsaturated fatty acids are reduced in the brains of people with schizophrenia.
Scientists are reporting development of a healthy "designer fat" that, when added to infant formula, provides a key nutrient that premature babies need in high quantities, but isn't available in large enough amounts in their mothers' milk.
For the first time, researchers at the University of California, San Diego have peered inside a living mouse cell and mapped the processes that power the celebrated health benefits of omega-3 fatty acids. More profoundly, they say their findings suggest it may be possible to manipulate these processes to short-circuit inflammation before it begins, or at least help to resolve inflammation before it becomes detrimental.
After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.
Purdue University researchers have created a new imaging technology that reveals subtle changes in breast tissue, representing a potential tool to determine a woman's risk of developing breast cancer and to study ways of preventing the disease.
Is obesity in infants "programmed" in the womb? Previously, researchers assumed that consumption of "bad" fats during pregnancy contribute to excessive infant adipose tissue growth and that "good" omega-3 fatty acids prevent expansive adipose tissue development. A study run by the Technische Universit-t M-nchen showed no evidence to support this "perinatal programming" theory.
A team led by scientists from The Scripps Research Institute has identified a new metabolic pathway for controlling brain inflammation, suggesting strategies for treating it.
Ibuprofen, naproxen, and related non-steroidal anti-inflammatory drugs (NSAIDs) - the subjects of years of study - still have some secrets to reveal about how they work.
University of Kansas scientists have found new evidence that infant formulas fortified with long chain polyunsaturated fatty acids (LCPUFA) are good for developing brains and hearts.
A diet rich in omega-3s reduces the severity of brain damage after a stroke, according to a study conducted by Universit- Laval researchers. The team, co-directed by professors Jasna Kriz and Fr-d-ric Calon, showed that the extent of brain damage following a stroke was reduced by 25% in mice that consumed DHA type omega-3s daily.
Over the past decade, much progress has been made regarding the understanding and promise of personalized medicine. Scientists are just beginning to consider the impact of gene-diet interactions in different populations in regards to disease prevention and treatment.
More than one-third of the world's population suffers from hypertension and cardiovascular disease. The U.S. Agency for Healthcare Quality and Research has reported that Americans spent $29 billion for non-prescription cardiovascular drugs alone in 2008.
Orexo AB announces today that its partner ProStrakan Group plc has launched Abstral in the United States.
Orexo AB announces the positive outcome following completion of the initial pharmacokinetic trial in the OX51 project. The project is aimed at developing a sublingual dosage form tailored to treat acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief.
Orexo AB today announces that ProStrakan's partner, Paladin Labs Inc. has been informed by Health Canada, the Canadian Government Department with responsibility for public health, that it has approved Abstral.
Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.
Orexo AB and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia Pacific region for Abstral™, Orexo's product for the treatment of breakthrough cancer pain.
The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.